KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

NovoCure (NVCR) Leases (2019 - 2026)

NovoCure's Leases history spans 8 years, with the latest figure at $45.5 million for Q1 2026.

  • On a quarterly basis, Leases fell 6.26% to $45.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $45.5 million, a 6.26% decrease, with the full-year FY2025 number at $47.3 million, up 74.51% from a year prior.
  • Leases hit $45.5 million in Q1 2026 for NovoCure, down from $47.3 million in the prior quarter.
  • Over the last five years, Leases for NVCR hit a ceiling of $48.5 million in Q1 2025 and a floor of $18.3 million in Q2 2022.
  • Historically, Leases has averaged $32.5 million across 5 years, with a median of $29.0 million in 2023.
  • Biggest five-year swings in Leases: decreased 22.15% in 2024 and later soared 74.51% in 2025.
  • Tracing NVCR's Leases over 5 years: stood at $23.6 million in 2022, then surged by 47.63% to $34.8 million in 2023, then dropped by 22.15% to $27.1 million in 2024, then soared by 74.51% to $47.3 million in 2025, then fell by 3.91% to $45.5 million in 2026.
  • Business Quant data shows Leases for NVCR at $45.5 million in Q1 2026, $47.3 million in Q4 2025, and $48.4 million in Q3 2025.